Phase of Development: In Vivo Proof of Concept
Mechanism of Action: Tau Proteostasis, Propagation and Clearance
Compound Type/Modality: Small Molecule
Small molecule autophagy modulators for tauopathies
David Rubinsztein, MB ChB, BSc(Med), PhD
Deputy Director, Cambridge Institute for Medical Research
Professor of Molecular Neurogenetics, University of Cambridge
UK Dementia Research Institute Group Leader

For further information about this program Contact:
-
Project Lead
Drug Discovery drugdiscovery@rainwatercf.org